Evidence map›Paper›PMID 35743795›Full record

ArticleJournal of personalized medicine2022

Ethical and Legal Aspects of Technology-Assisted Care in Neurodegenerative Disease.

Bjoern Schmitz-Luhn, Jennifer Chandler, On Behalf Of The iCARE-Pd Consortium

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bjoern Schmitz-LuhnCenter for Life Ethics, Bonn University, 53113 Bonn, Germany.
Jennifer ChandlerBertram Loeb Research Chair, Centre for Health Law, Policy and Ethics, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
On Behalf Of The iCARE-Pd Consortium

Funding

Federal Ministry of Education and Research 01ED1904B
6 · The paper itself

Abstract

Technological solutions are increasingly seen as a way to respond to the demands of managing complex chronic conditions, especially neurodegenerative diseases such as Parkinson's Disease. All of these new possibilities provide a variety of chances to improve the lives of affected persons and their families, friends, and caregivers. However, there are also a number of challenges that should be considered in order to safeguard the interests of affected persons. In this article, we discuss the ethical and legal considerations associated with the use of technology-assisted care in the context of neurodegenerative conditions.

Indexed as

ethics and law of medicine and technologyliabilitymedical educationneurodegenerative diseasestechnology-assisted care

Identifiers

PMID35743795
PMCPMC9225587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.